Cannabidiol is a new compound discovered by researchers that have been shown to reduce anxiety in patients suffering from social phobia. It was found that it inhibits THC-elicited paranoid symptoms. Another study also found that it inhibited the development of hippocampal-dependent memory impairment in rats. According to the journal Neuropsychopharmacology, it suppressed nitric oxide production in beta-amyloid-stimulated PC12 neurons.
In addition to reducing seizure frequency and severity, Cannabidiol also reduces adverse events, such as seizures. In animal studies, it is associated with fewer adverse events and increased plasma levels. The benefits of this can be seen in humans, too, although the FDA has not evaluated it as yet. It is still necessary to do further research before recommending it for human use.
A recent study published in the journal Neuropsychopharmacology reported that cannabidiol reduced the anxiety levels of patients suffering from social phobia. This study used it to treat patients with phenobarbital-induced apathy. In rats, it inhibited the reward-facilitating effects of morphine. This was further verified in a recent open-label trial in multiple sclerosis.
Study more- https://bit.ly/3MmZfNJ
In the study conducted by Crippa JAS and Spriggs, it also inhibited hyperlocomotion in mice and rats. Furthermore, it decreased cigarette consumption among people who smoked tobacco, while it improved memory and concentration in rats. The study concluded that it may be an effective treatment for the symptoms of heroin addiction. The results showed that it reduced the consumption of cigarettes in both human and animal experiments.
In animal studies, it inhibited the growth of human glioma cells. The study also showed that it inhibited amphetamine-induced oxidative stress. It also prevented ischemia and analgesia and reduced the risk of cancer. The findings were presented at the 34th National Congress of the Italian Society of Pharmacology in 2009.
